Genetic variants in inducible nitric oxide synthase gene are associated with the risk of radiation-induced lung injury in lung cancer patients receiving definitive thoracic radiation

In 2018, lung cancer was the most common cancer and the most common cause of cancer death, accounting for a 1.76 million deaths. Radiotherapy (RT) is a widely used and effective non-surgical cancer treatment that induces remission in, and even cures, patients with lung cancer. However, RT faces some restrictions linked to the radioresistance and treatment toxicity, manifesting in radiation-induced lung injury (RILI). About 30–40% of lung cancer patients will develop RILI, which next to the local recurrence and distant metastasis is a substantial challenge to the successful management of lung cancer treatment. These data indicate an urgent need of looking for novel, precise biomarkers of individual response and risk of side effects in the course of RT. The aim of this review was to summarize both preclinical and clinical approaches in RILI monitoring that could be brought into clinical practice. Next to transforming growth factor-β1 (TGFβ1) that was reported as one of the most important growth factors expressed in the tissues after ionizing radiation (IR), there is a group of novel, potential biomarkers—microRNAs—that may be used as predictive biomarkers in therapy response and disease prognosis.

Download Full-text

Radiomic analysis of planning computed tomograms for predicting radiation-induced lung injury and outcome in lung cancer patients treated with robotic stereotactic body radiation therapy

Strahlentherapie und Onkologie ◽

10.1007/s00066-019-01452-7 ◽

2019 ◽

Vol 195 (9) ◽

pp. 830-842 ◽

Cited By ~ 11

Author(s):

Khaled Bousabarah ◽

Susanne Temming ◽

Mauritius Hoevels ◽

Jan Borggrefe ◽

Wolfgang W. Baus ◽

...

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Lung Injury ◽

Cancer Patients ◽

Stereotactic Body Radiation Therapy ◽

Lung Cancer Patients ◽

Stereotactic Body Radiation ◽

Radiation Induced

Download Full-text

Multi-center randomized trial of Compound Kushen injection for decreasing radiation- induced thoracic toxicity in lung cancer patients

10.21203/rs.3.rs-135592/v2 ◽

2021 ◽

Author(s):

Qingxi Yu ◽

Jun Wang ◽

Fan Wang ◽

Haitao Yin ◽

Xia Li ◽

...

Keyword(s):

Lung Cancer ◽

Adverse Events ◽

Cancer Patients ◽

Control Group ◽

Lung Cancer Patients ◽

Thoracic Radiation ◽

Radiation Induced ◽

And Control ◽

Compound Kushen Injection ◽

Experimental Group

Abstract Background: Thoracic radiation therapy plays an important role in the treatment of inoperable lung cancer. However, radiotherapy-induced toxicity poses an important challenge for radiation oncologists. Research has shown that Compound Kushen Injection (CKI) has anti-inflammatory activity and can reduce toxicity when given with chemotherapy. So, we hypothesis CKI can decrease chemoradiotherapy-induced thoracic toxicity in lung cancer patients and conducted this randomized, multi-center study. Methods: A prospective, open, randomized, multi-center，phase IV trial was performed, in which a total of 296 lung cancer patients were enrolled and randomly divided 1:1 into experimental and control groups. The control group received standard chemoradiotherapy including precise thoracic radiotherapy (60 Gy/30 fractions/6 weeks) plus concurrent platinum-based chemotherapy. The experimental group received standard chemoradiotherapy plus CKI via mainline treatments of 250 ml CKI (20 ml diluted in 0.9% normal saline) daily for 20 continuous days. The incidence of adverse events and severity of thoracic toxicity after treatment were observed according to version 4.0 of the Common Terminology Criteria for Adverse Events. Adverse drug reactions (ADRs) and quality of life (QLQ-C30) also were compared between the two groups.Results: Two hundred ninety-one qualifying patients were included in the statistical analysis. Symptomatic radiation-induced thoracic toxicity was lower in the experimental group than in the control group (14.1% vs 25.6%, p=0.017). According to QLQ-C30 questionnaire findings, CKI provided superior outcomes related to pain relief, relieving fatigue, social functioning and emotional functioning (p<0.05). The rates of adverse events (26.4% vs 30.8%, p>0.05) and severe adverse events (5.4% vs 2.8%, p>0.05) did not differ significantly between the experimental and control groups.Conclusion: CKI significantly alleviated symptomatic radiation-induced thoracic toxicity, as well as pain, when given with chemoradiotherapy for lung cancer treatment.

Download Full-text

Radiation-Induced Lung Injury and Inflammation in Mice: Role of Inducible Nitric Oxide Synthase and Surfactant Protein D

Toxicological Sciences ◽

10.1093/toxsci/kfu255 ◽

2014 ◽

Vol 144 (1) ◽

pp. 27-38 ◽

Cited By ~ 25

Author(s):

Rama Malaviya ◽

Andrew J. Gow ◽

Mary Francis ◽

Elena V. Abramova ◽

Jeffrey D. Laskin ◽

...

Keyword(s):

Nitric Oxide ◽

Nitric Oxide Synthase ◽

Lung Injury ◽

Inducible Nitric Oxide Synthase ◽

Surfactant Protein ◽

Surfactant Protein D ◽

Radiation Induced ◽

Oxide Synthase ◽

Inducible Nitric Oxide

Download Full-text

Associations ofLIG4andHSPB1Genetic Polymorphisms with Risk of Radiation-Induced Lung Injury in Lung Cancer Patients Treated with Radiotherapy

BioMed Research International ◽

10.1155/2015/860373 ◽

2015 ◽

Vol 2015 ◽

pp. 1-6

Author(s):

Feng Xu ◽

Ji-Chang Han ◽

Ya-Jun Zhang ◽

Yi-Jie Zhang ◽

Xiao-Chun Liu ◽

...

Keyword(s):

Lung Cancer ◽

Lung Injury ◽

Cancer Patients ◽

Genetic Polymorphisms ◽

Genotype Distribution ◽

Chi Square ◽

Lung Cancer Patients ◽

Significant Difference ◽

Radiation Induced ◽

Grade 3

Objective.This study aims to explore the correlations of genetic polymorphisms inLIG4andHSPB1genes with the radiation-induced lung injury (RILI), especially radiation pneumonitis (RP), in lung cancer patients.Methods.A total of 160 lung cancer patients, who were diagnosed with inoperable lung cancer and received radiotherapy, were included in the present study from September 2009 to December 2011. TaqMan Real-Time PCR (RT-PCR) was used to verify the SNPs ofLIG4andHSPB1genes. Chi-square criterion was used to compare the differences in demographic characteristics, exposure to risk factors, and SNPs genotypes. Crude odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated by logistic regression analysis. All statistical analyses were conducted in SPSS 18.0.Results.A total of 32 (20.0%) lung cancer patients had RP after receiving radiotherapy. Of the 32 cases, 4 cases were of grade 2, 24 cases were of grade 3, and 4 cases were of grade 4. However, our results indicated that the general condition and treatment of all patients had no significant difference with RP risk(P>0.05). Meanwhile, our results revealed that there was no significant association between the frequencies ofLIG4 rs1805388andHSPB1 rs2868371genotype distribution and the risk of RP(P>0.05).Conclusion.In conclusion, we demonstrated that the genetic polymorphisms inLIG4 rs1805388andHSPB1 rs2868371were not obviously correlated with the risk of RP and RILI of lung cancer.

Download Full-text